Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases.

The letter published in the Blood Cancer Journal discusses the use of luspatercept for treating anemia in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study involved 16 patients with various hematological diseases, with 81.3% achieving an erythroid response after luspatercept treatment. The treatment was generally well-tolerated, with mild adverse events reported. The study suggests that luspatercept could be an effective option for managing anemia post-allo-HSCT, although further research is needed due to the study's limitations. [Extracted from the article]